Study Evaluating HKI-272 in Tumors
Launched by PUMA BIOTECHNOLOGY, INC. · Sep 2, 2005
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Her2/neu or Her1/EGFR positive cancer
- • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
- Exclusion Criteria:
- • Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent of greater than 300 mg/m\^2
- • Patients with significant cardiac risk factors
- • Active central nervous system metastasis
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Leveraging advanced scientific research, Puma is dedicated to addressing unmet medical needs by bringing to market targeted therapies that aim to improve patient outcomes. With a robust pipeline of investigational drugs, the company is committed to clinical excellence and collaboration with healthcare professionals to enhance the lives of patients living with cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Boston, Massachusetts, United States
Tampa, Florida, United States
Nashville, Tennessee, United States
Cleveland, Ohio, United States
Patients applied
Trial Officials
Puma
Study Director
Biotechnology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials